Literature DB >> 5812915

Esterases of the polymorphonuclear leukocyte capable of hydrolyzing acetyl DL-phenyl-alanine beta-naphthyl ester. Relationship to the activatable esterase of chemotaxis.

E L Becker, P A Ward.   

Abstract

Previous published work has led to the hypothesis that the activatable esterase of chemotaxis is a serine esterase of the rabbit polymorphonuclear leukocyte existing in an inert, phosphonate insusceptible form, which after activation is capable of hydrolyzing aromatic amino acid esters and being inhibited by phosphonates. In the present study, directed to the testing of this hypothesis, we have shown that rabbit peritoneal polymorphonuclear leukocytes contain three esterases capable of hydrolyzing the aromatic amino acid ester, acetyl DL-phenylalanine beta-naphthyl ester. Two of these esterases, esterase 1 and esterase 2, are inhibited by various p-nitrophenyl ethyl phosphonate esters. The inhibition of each esterase is irreversible and progressive with time. When the logarithm of the esterase activity remaining after cell and inhibitor have been in contact for a constant time is plotted against the concentration of inhibitor, a straight line results. These results support the conclusion that both esterases are serine esterases. The third esterase, esterase 3, differs from the other two by its inability to be inactivated by any of the phosphonates no matter how high the concentration of phosphonate or prolonged the period of incubation of cell with phosphonate. The activity of esterase 1 is at least 10,000 times more easily inhibited by phosphonates than is that of esterase 2; incubating rabbit polymorphonuclear leukocytes for 15 min at 27 degrees C with 10(-9)-10(-8)M concentrations of various phosphonates inactivates esterase 1, but it required 10(-6)-10(-4)M concentrations of the same phosphonates to inhibit esterase 2. The inhibition profiles of esterase 1 are distinctly different from those of esterase 2 when the two esterases are tested with the phenylalkylphosphonates, chloroalkylphosphonates, and alkylphosphonates. The inhibition profile of esterase 1 is essentially the same as that of the activatable esterase of chemotaxis obtained previously when the same three homologous series of phosphonates were tested for their ability to protect against deactivation by the chemotactic factor or give chemotactic-dependent inhibition. It is tentatively concluded that esterase 1 of the rabbit peritoneal neutrophil is the activated form of the activatable esterase of chemotaxis.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5812915      PMCID: PMC2138612          DOI: 10.1084/jem.129.3.569

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

1.  ENZYME INHIBITORY ACTIVITY OF CERTAIN PHOSPHONATE ESTERS AGAINST CHYMOTRYPSIN, TRYPSIN AND ACETYLCHOLINESTERASE.

Authors:  B J BOONE; E L BECKER; D H CANHAM
Journal:  Biochim Biophys Acta       Date:  1964-06-01

2.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

3.  The relationship of enzyme inhibitory activity to the structure of n-alkylphosphonate and phenylalkyl-phosphonate esters.

Authors:  E L BECKER; T R FUKUTO; B BOONE; D C CANHAM; E BOGER
Journal:  Biochemistry       Date:  1963 Jan-Feb       Impact factor: 3.162

4.  A COMPARISON OF THE SPECIFICITY OF INHIBITION BY PHOSPHONATE ESTERS OF THE FIRST COMPONENT OF COMPLEMENT AND THE ANTIGEN-INDUCED RELEASE OF HISTAMINE FROM GUINEA PIG LUNG.

Authors:  E L BECKER; K F AUSTEN
Journal:  J Exp Med       Date:  1964-10-01       Impact factor: 14.307

5.  Mechanisms of immunologic injury of rat peritoneal mast cells. I. The effect of phosphonate inhibitors on the homocytotropic antibody-mediated histamine release and the first component of rat complement.

Authors:  E L Becker; K F Austen
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

6.  The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase.

Authors:  P A Ward; E L Becker
Journal:  J Exp Med       Date:  1968-04-01       Impact factor: 14.307

7.  Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes.

Authors:  E L Becker; P A Ward
Journal:  J Exp Med       Date:  1967-06-01       Impact factor: 14.307

8.  Mechanisms of the inhibition of chemotaxis by phosphonate esters.

Authors:  P A Ward; E L Becker
Journal:  J Exp Med       Date:  1967-06-01       Impact factor: 14.307

9.  Mechanisms of immunologic injury of rat peritoneal mast cells. II. Complement requirement and phosphonate ester inhibition of release of histamine by rabbit anti-rat gamma globulin.

Authors:  K F Austen; E L Becker
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

  9 in total
  5 in total

1.  Leukotactic factors in health and disease.

Authors:  P A Ward
Journal:  Am J Pathol       Date:  1971-09       Impact factor: 4.307

2.  Inhibition of neutrophil chemotaxis by protease inhibitors. Differential effect of inhibitors of serine and thiol proteases.

Authors:  J B Barna; R R Kew
Journal:  Inflammation       Date:  1995-10       Impact factor: 4.092

3.  Human leukocyte elastase, cathepsin G, and lactoferrin: family of neutrophil granule glycoproteins that bind to an alveolar macrophage receptor.

Authors:  E J Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

4.  Role of a peptidase in phagocyte chemotaxis.

Authors:  S Aswanikumar; E Schiffmann; B A Corcoran; S M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

5.  The relationship of the chemotactic behavior of the complement-derived factors, C3a, C5a, and C567, and a bacterial chemotactic factor to their ability to activate the proesterase 1 of rabbit polymorphonuclear leukocytes.

Authors:  E L Becker
Journal:  J Exp Med       Date:  1972-02-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.